Edition:
India

Axcella Health Inc (AXLA.OQ)

AXLA.OQ on NASDAQ Stock Exchange Global Market

7.91USD
16 Aug 2019
Change (% chg)

-- (--)
Prev Close
$7.91
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
--
52-wk High
$15.94
52-wk Low
$6.19

Summary

Name Age Since Current Position

William Hinshaw

President, Chief Executive Officer

Thomas Leggett

2018 Chief Financial Officer, Senior Vice President of Finance

Tony Tramontin

Senior Vice President of Research and Development , Chief Scientific Officer

Manu Chakravarthy

Senior Vice President of Clinical Development, Chief Medical Officer

Stephen Mitchener

Senior Vice President, chief Business Officer

Biographies

Name Description

William Hinshaw

Mr.Bill Hinshaw is President, Chief Executive Officer of Company.Bill Hinshaw brings 30 years of highly successful, geo-diverse experience in leading commercial, medical, clinical development, strategic, financial, legal, policy and operations teams for the life sciences industry.

Thomas Leggett

Mr. Thomas Leggett is Chief Financial Officer, Senior Vice President of Finance of the Company. Mr. Leggett began his career in Management Consulting at Mitchell Madison Group before transitioning to Elance, Inc., a Kleiner, Perkins, Caufield and Byers-backed internet start-up company. After earning his MBA, he started his investment banking career in the J.P. Morgan Securities Healthcare Group. His transactions included the acquisition of Guidant Corporation by Boston Scientific, the initial public offering of Coley Pharmaceuticals and an equity offering for Celgene. Following his time at J.P. Morgan, Leggett became a Vice President at Lazard Frères & Company, where he worked on the acquisitions of PolyMedica by Medco Health Solutions and Viasys Healthcare by Cardinal Health, among other transactions. Mr. Leggett then spent five years at UBS Securities as an Executive Director in the Healthcare Group with a primary focus in the biopharmaceutical sector. His transactions during this time included advising Akebia Therapeutics, Amgen, Baxter International, Bristol-Myers Squibb and Momenta Pharmaceuticals. In 2015, Leggett joined Purdue Pharma L.P. as Treasurer and Head of Business Development Finance. During his time at Purdue, the company announced five strategic transactions, including the worldwide collaboration to develop and commercialize lemborexant with Eisai Co., Ltd. and the alliance for the joint U.S. commercialization of Symproic® (naldemedine) with Shionogi & Co., Ltd. Mr. Leggett received his Bachelor of Arts in Economics from Columbia University and earned his Master’s in Business Administration in Finance from The Wharton School at the University of Pennsylvania.

Tony Tramontin

Mr.Tony Tramontin Ph.D. is Senior Vice President of Research and Development , Chief Scientific Officer of Company.Dr. Tramontin was a Partner in McKinsey & Company’s Global Healthcare Practice. Across a 13 year career, he advised biopharma executive teams on a wide variety of strategic, operational and organizational topics across the value chain. The majority of his work, however, focused specifically on research, medicine development and early aspects of commercialization. He co-founded and led McKinsey’s technical service line that helps biopharma executives with R&D project investment decisions, portfolio prioritization, risk management, therapeutic area strategy, and product launch strategy. Before joining McKinsey, Dr. Tramontin was an experimental neuroscientist conducting neural stem cell research at The Rockefeller University and in The University of California San Francisco Department of Neurosurgery. Dr. Tramontin holds a Ph.D. in Biology (neuroscience and endocrinology) from the University of Washington and a B.A. in Business from the University of Notre Dame.

Manu Chakravarthy

Mr.Manu V. Chakravarthy M.D., Ph.D. is Senior Vice President of Clinical Development, Chief Medical Officer of Company.Dr. Chakravarthy served as the Global Head of External R&D in diabetes and cardiovascular research at Eli Lilly & Co where he was responsible for external innovation efforts, including the identification/evaluation of novel therapeutics, platforms, and technologies for in/out-licensing, establishing academic collaborations, and consortia management across the value chain to complement and enhance Lilly’s internal R&D portfolio. He also served as the industry co-leader of the Innovative Medicine Initiative’s LITMUS project, one of the largest public-private consortia efforts to elucidate noninvasive biomarkers for NAFLD. Before his global leadership role at Lilly, Dr. Chakravarthy spent more than 7 years at Merck & Co., where he began his industry career in Experimental Medicine as an associate director and progressively gained increasing experience across the R&D spectrum from discovery, clinical pharmacology, biomarker development and late-stage drug development in endocrine, metabolic, neuroscience and anti-viral therapeutic areas. During this time, he assumed positions of increasing responsibility and leadership within the company, ultimately serving as a Distinguished Scientist and led the clinical pharmacology groups in Discovery Medicine for groups in diabetes and cardiometabolic diseases within Translational Medicine. Dr. Chakravarthy received his medical degree from the University of Texas Houston Medical School, his doctorate in cell biology & physiology from the University of Texas Graduate School of Biomedical Sciences and the MD Anderson Cancer Center, and his bachelor’s degree in Liberal Arts from St. John’s University. He completed a residency in Internal Medicine at the Hospital of the University of Pennsylvania and clinical Fellowship in Endocrinology, Diabetes & Metabolism at the Barnes-Jewish Hospital in St Louis.

Stephen Mitchener

Mr.Stephen Mitchener is Senior Vice President, chief Business Officer of Company.Dr. Mitchener built a 15-year career at Novartis Pharmaceuticals, most recently as Head of U.S. Oncology Strategy, Partnering and Operations. In this Executive team role, he led all business development and collaborations for Novartis U.S. Oncology across academic, big data, pipeline, product and technology partnering initiatives. In addition, he had responsibility for Loss of Exclusivity (LoE), Companion Diagnostic (CDx) and Enterprise Operations for a $5 billion P&L. Dr. Mitchener has also led both commercial evaluations for successful global product acquisitions and BD&L activities for multiple products. In his commercial roles, Dr. Mitchener helped lead and transition assets in immunology, infectious diseases, oncology and rare diseases from research through commercialization for the company. Previously, Dr. Mitchener was the Business Franchise Head at Novartis Oncology for Australia & New Zealand, managing 13 products including 5 new launches. Dr. Mitchener was a Board Observer for COTA Healthcare, where he provided guidance on operations, strategy, and Series C financing on behalf of Novartis Oncology. Dr. Mitchener received his Doctor of Pharmacy degree from the University of North Carolina at Chapel Hill and conducted his Postdoctoral work at Rutgers University and Novartis Oncology.

Basic Compensation

Options Compensation